Recognizing and treating early relapse of multiple myeloma (MM) is a challenge for healthcare professionals. This program is designed to improve clinicians’ ability to distinguish between relapse and progression of disease in MM. In addition, the program compares the efficacy and safety of carfilzomib- and pomalidomide-based regimens in the treatment of relapsed MM, applies current and emerging treatment approaches to MM patients in early relapse, and reviews common adverse events that occur when using combination regimens to treat early relapsed myeloma.